Brainsway Ltd. (TASE:BRIN) today announced that it has obtained approval for two new trials for its Deep TMS transcranial magnetic stimulation device.
In the first study, the company has obtained approval from the ethics committee of the US National Institute on Drug Abuse (NIDA), a unit of the National Institutes of Health (NIH), to conduct a clinical trial to test the efficiency of the company's Deep TMS for the treatment of cocaine addiction.
The trial will include 30 addicts, and is due to begin in a few weeks. NIDA will finance the trial. The lead researcher will be Dr. David A. Gorelick, NIDA's intramoral research program head.
Brainsway also announced that the ethics committee of the Charite University Hospital in Berlin has approved a clinical trial to test the safety and effectiveness of Deep TMS for the treatment of multiple sclerosis. The 16-week trial will include 36 patients.
The trial aims to examine the effectiveness of Deep TMS will be examined by questionnaires about the patients' exhaustion, depression, condition of multiple sclerosis, blood, other factors. The company expects to begin the trial in the third quarter of 2009.
The trials are part of Brainsway's strategy to carry out human clinical trials of Deep TMS to test its efficiency in treating various illnesses, including depression, Alzheimer's, marijuana addiction, and Parkinson's disease.
Brainsway's share rose 5.2% by early afternoon to NIS 6.45.
Published by Globes [online], Israel business news - www.globes-online.com - on April 23, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009